| [1] |
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| [2] |
SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3): 233-254.
|
| [3] |
HUANG J J, LUCERO-PRISNO D E 3rd, ZHANG L, et al. Updated epidemiology of gastrointestinal cancers in East Asia[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(5): 271-287.
|
| [4] |
MORRIS V K, KENNEDY E B, BAXTER N N, et al. Treatment of metastatic colorectal cancer: ASCO guideline[J]. J Clin Oncol, 2023, 41(3): 678-700.
|
| [5] |
SHIN A E, GIANCOTTI F G, RUSTGI A K. Metastatic colorectal cancer: mechanisms and emerging therapeutics[J]. Trends Pharmacol Sci, 2023, 44(4): 222-236.
|
| [6] |
LIU B L, ZHOU H Y, TAN L C, et al. Exploring treatment options in cancer: Tumor treatment strategies[J]. Sig Transduct Target Ther, 2024, 9(1): 175.
|
| [7] |
LAWRENCE R, WATTERS M, DAVIES C R, et al. Circulating tumour cells for early detection of clinically relevant cancer[J]. Nat Rev Clin Oncol, 2023, 20(7): 487-500.
|
| [8] |
LIU A Y, YU C X, QIU C, et al. PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis[J]. Oncogene, 2023, 42(19): 1572-1584.
|
| [9] |
SABOUNI E, NEJAD M M, MOJTABAVI S, et al. Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways[J]. Biomedecine Pharmacother, 2023, 160: 114395.
|
| [10] |
THAPA R, AFZAL O, AFZAL M, et al. From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression[J]. Pathol Res Pract, 2024, 253: 154959.
|
| [11] |
BARDELČÍKOVÁ A, ŠOLTYS J, MOJŽIŠ J. Oxidative stress, inflammation and colorectal cancer: an overview[J]. Antioxidants (Basel), 2023, 12(4): 901.
|
| [12] |
NIGAM M, MISHRA A P, DEB V K, et al. Evaluation of the association of chronic inflammation and cancer: Insights and implications[J]. Biomed Pharmacother, 2023, 164: 115015.
|
| [13] |
CHEN G M, JIANG N, ZHENG J P, et al. Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus [J]. Int J Biol Macromol, 2023, 241: 124386.
|
| [14] |
SHA W J, ZHAO B, WEI H Z, et al. Astragalus polysaccharide ameliorates vascular endothelial dysfunction by stimulating macrophage M2 polarization via potentiating Nrf2/HO-1 signaling pathway[J]. Phytomedicine, 2023, 112: 154667.
|
| [15] |
YANG Q, MENG D D, ZHANG Q Y, et al. Advances in research on the anti-tumor mechanism of Astragalus polysaccharides[J]. Front Oncol, 2024, 14: 1334915.
|
| [16] |
YANG C, LI D, KO C N, et al. Active ingredients of traditional Chinese medicine for enhancing the effect of tumor immunotherapy[J]. Front Immunol, 2023, 14: 1133050.
|
| [17] |
XU Q, CHENG W, WEI J R, et al. Synergist for antitumor therapy: Astragalus polysaccharides acting on immune microenvironment[J]. Discov Oncol, 2023, 14(1): 179.
|
| [18] |
XIONG H T, HAN X P, CAI L, et al. Natural polysaccharides exert anti-tumor effects as dendritic cell immune enhancers[J]. Front Oncol, 2023, 13: 1274048.
|
| [19] |
CHEN R Q, LI Y T, ZUO L, et al. Astragalus polysaccharides inhibits tumor proliferation and enhances cisplatin sensitivity in bladder cancer by regulating the PI3K/AKT/FoxO1 axis[J]. Int J Biol Macromol, 2025, 311: 143739.
|
| [20] |
WANG F H, ZHANG X T, TANG L, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023[J]. Cancer Commun, 2024, 44(1): 127-172.
|
| [21] |
SATHE A, MASON K, GRIMES S M, et al. Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated macrophages and fibroblasts[J]. Clin Cancer Res, 2023, 29(1): 244-260.
|
| [22] |
BOND M J G, BOLHUIS K, LOOSVELD O J L, et al. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group[J]. Lancet Oncol, 2023, 24(7): 757-771.
|
| [23] |
LINARES J, SALLENT-ARAGAY A, BADIA-RAMENTOL J, et al. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy[J]. Nat Commun, 2023, 14(1): 746.
|
| [24] |
FASANO M, PIROZZI M, MICELI C C, et al. TGF-β modulated pathways in colorectal cancer: new potential therapeutic opportunities[J]. Int J Mol Sci, 2024, 25(13): 7400.
|
| [25] |
CHEN Z D, LIANG H Y, YAN X X, et al. Astragalus polysaccharide promotes autophagy and alleviates diabetic nephropathy by targeting the lncRNA Gm41268/PRLR pathway[J]. Ren Fail, 2023, 45(2): 2284211.
|
| [26] |
SUN L I, ZHUO S C, LI X X, et al. Astragalus polysaccharide enhances the therapeutic efficacy of cisplatin in triple-negative breast cancer through multiple mechanisms[J]. Oncol Res, 2025, 33(3): 641-651.
|
| [27] |
NIAN Q, LIU R X, ZENG J H. Unraveling the pathogenesis of myelosuppression and therapeutic potential of natural products[J]. Phytomedicine, 2024, 132: 155810.
|
| [28] |
TYLUTKA A, WALAS Ł, ZEMBRON-LACNY A. Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis[J]. Front Immunol, 2024, 15: 1330386.
|
| [29] |
GUO Q, JIN Y Z, CHEN X Y, et al. NF-κB in biology and targeted therapy: new insights and translational implications[J]. Sig Transduct Target Ther, 2024, 9(1): 53.
|
| [30] |
HU Z Y, SUI Q H, JIN X, et al. IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma[J]. J Exp Clin Cancer Res, 2024, 43(1): 63.
|
| [31] |
LEONE G M, MANGANO K, PETRALIA M C, et al. Past, present and (foreseeable) future of biological anti-TNF alpha therapy[J]. J Clin Med, 2023, 12(4): 1630.
|
| [32] |
AUYEUNG K K, HAN Q B, KO J K. Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers[J]. Am J Chin Med, 2016, 44(1): 1-22.
|
| [33] |
WU Q, YANG Z P, NIE Y Z, et al. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches[J]. Cancer Lett, 2014, 347(2): 159-166.
|
| [34] |
DUAN C Y, YU M J, XU J Y, et al. Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges[J]. Biomed Pharmacother, 2023, 162: 114643.
|